451 related articles for article (PubMed ID: 33692246)
1. Preoperative and long-term efficacy and safety of lanreotide autogel in patients with thyrotropin-secreting pituitary adenoma: a multicenter, single-arm, phase 3 study in Japan.
Shimatsu A; Nakamura A; Takahashi Y; Fujio S; Satoh F; Tahara S; Nishioka H; Takano K; Yamashita M; Arima H; Tominaga A; Tateishi S; Matsushita Y
Endocr J; 2021 Jul; 68(7):791-805. PubMed ID: 33692246
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide.
Kuhn JM; Arlot S; Lefebvre H; Caron P; Cortet-Rudelli C; Archambaud F; Chanson P; Tabarin A; Goth MI; Blumberg J; Catus F; Ispas S; Beck-Peccoz P
J Clin Endocrinol Metab; 2000 Apr; 85(4):1487-91. PubMed ID: 10770186
[TBL] [Abstract][Full Text] [Related]
3. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas.
Gancel A; Vuillermet P; Legrand A; Catus F; Thomas F; Kuhn JM
Clin Endocrinol (Oxf); 1994 Mar; 40(3):421-8. PubMed ID: 8187308
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.
Shimatsu A; Teramoto A; Hizuka N; Kitai K; Ramis J; Chihara K
Endocr J; 2013; 60(5):651-63. PubMed ID: 23337477
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN).
An Z; Lei T; Duan L; Hu P; Gou Z; Zhang L; Durand-Gasselin L; Wang N; Wang Y; Gu F;
BMC Endocr Disord; 2020 May; 20(1):57. PubMed ID: 32366244
[TBL] [Abstract][Full Text] [Related]
6. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage.
Lucas T; Astorga R; Catalá M;
Clin Endocrinol (Oxf); 2003 Apr; 58(4):471-81. PubMed ID: 12641631
[TBL] [Abstract][Full Text] [Related]
7. Lanreotide autogel-induced tumour shrinkage in thyrotropin-secreting pituitary macroadenomas.
Paniagua AE; Bernabeu I; Leskela S; Marazuela M
Clin Endocrinol (Oxf); 2011 Mar; 74(3):406-8. PubMed ID: 21091752
[No Abstract] [Full Text] [Related]
8. Primary Medical Treatment of Thyrotropin-Secreting Pituitary Adenomas by First-Generation Somatostatin Analogs: A Case Study of Seven Patients.
Rimareix F; Grunenwald S; Vezzosi D; Rivière LD; Bennet A; Caron P
Thyroid; 2015 Aug; 25(8):877-82. PubMed ID: 26244412
[TBL] [Abstract][Full Text] [Related]
9. Pituitary macroadenoma secreting thyrotropin and growth hormone: remission of bihormonal hypersecretion in response to lanreotide therapy.
Shimon I; Nass D; Gross DJ
Pituitary; 2001 Sep; 4(4):265-9. PubMed ID: 12501978
[TBL] [Abstract][Full Text] [Related]
10. Response of thyrotropin-secreting pituitary tumors to preoperative lanreotide therapy. Report of two cases.
Tokutsu A; Okada Y; Torimoto K; Otsuka T; Narisawa M; Kurozumi A; Tanaka Y
Neuro Endocrinol Lett; 2020 Apr; 41(1):10-16. PubMed ID: 32338854
[TBL] [Abstract][Full Text] [Related]
11. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.
Caron PJ; Bevan JS; Petersenn S; Flanagan D; Tabarin A; Prévost G; Maisonobe P; Clermont A;
J Clin Endocrinol Metab; 2014 Apr; 99(4):1282-90. PubMed ID: 24423301
[TBL] [Abstract][Full Text] [Related]
12. Pregnancy in women after successful acromegaly treatment, including surgical removal of pituitary adenoma and postoperative therapy using lanreotide acetate.
Teltayev D; Akshulakov S; Ryskeldiev N; Mustafin K; Vyacheslav L
Gynecol Endocrinol; 2017; 33(sup1):50-51. PubMed ID: 29264984
[TBL] [Abstract][Full Text] [Related]
13. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide.
Karavitaki N; Turner HE; Adams CB; Cudlip S; Byrne JV; Fazal-Sanderson V; Rowlers S; Trainer PJ; Wass JA
Clin Endocrinol (Oxf); 2008 Jun; 68(6):970-5. PubMed ID: 18031313
[TBL] [Abstract][Full Text] [Related]
14. Short-term preoperative octreotide treatment for TSH-secreting pituitary adenoma.
Fukuhara N; Horiguchi K; Nishioka H; Suzuki H; Takeshita A; Takeuchi Y; Inoshita N; Yamada S
Endocr J; 2015; 62(1):21-7. PubMed ID: 25273395
[TBL] [Abstract][Full Text] [Related]
15. [Excellent response to lanreotide treatment of thyrotropin and prolactin secreting pituitary macroadenoma].
Murillo Sanchís J; Martín AL; Salinas Vert I; Sanmartí Sala A
Med Clin (Barc); 2000 Feb; 114(6):238. PubMed ID: 10757110
[No Abstract] [Full Text] [Related]
16. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.
Yamada S; Fukuhara N; Horiguchi K; Yamaguchi-Okada M; Nishioka H; Takeshita A; Takeuchi Y; Ito J; Inoshita N
J Neurosurg; 2014 Dec; 121(6):1462-73. PubMed ID: 25237847
[TBL] [Abstract][Full Text] [Related]
17. Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma.
Li ZQ; Quan Z; Tian HL; Cheng M
J Int Med Res; 2012; 40(2):517-24. PubMed ID: 22613412
[TBL] [Abstract][Full Text] [Related]
18. Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal.
Auriemma RS; Galdiero M; Grasso LF; Vitale P; Cozzolino A; Lombardi G; Colao A; Pivonello R
Eur J Endocrinol; 2010 May; 162(5):993-9. PubMed ID: 20156970
[TBL] [Abstract][Full Text] [Related]
19. CLINICAL OUTCOMES AND SELF-REPORTED SYMPTOMS IN PATIENTS WITH ACROMEGALY: AN 8-YEAR FOLLOW-UP OF A LANREOTIDE STUDY.
Khairi S; Sagvand BT; Pulaski-Liebert KJ; Tritos NA; Klibanski A; Nachtigall LB
Endocr Pract; 2017 Jan; 23(1):56-65. PubMed ID: 27682353
[TBL] [Abstract][Full Text] [Related]
20. Monotherapy with lanreotide depot for acromegaly: long-term clinical experience in a pituitary center.
Sagvand BT; Khairi S; Haghshenas A; Swearingen B; Tritos NA; Miller KK; Klibanski A; Nachtigall LB
Pituitary; 2016 Aug; 19(4):437-47. PubMed ID: 27155600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
